Swedish biotechnology company Alligator Bioscience AB (STO:ATORX) announced on Friday that the US Food and Drug Administration (FDA) has endorsed the 900 µg/kg dose of mitazalimab for its upcoming Phase 3 trial targeting metastatic pancreatic ductal adenocarcinoma (mPDAC).
This regulatory feedback affirms the company's dose selection strategy and marks a significant milestone in the clinical development of its CD40 agonist.
According to CEO Søren Bregenholt, the response from the FDA was both timely and constructive.
The company emphasised the importance of this step as it advances its Phase 3 programme in one of the most challenging oncology indications.
Alligator Bioscience is currently engaged in active discussions with potential partners to support the advancement of mitazalimab into late-stage clinical testing.
The planned Phase 3 study represents the next step in the company's strategy to address unmet medical needs in pancreatic cancer.
GRAIL reports positive results from Galleri multi-cancer early detection test registrational study
Bavarian Nordic sells US Priority Review Voucher for USD160m
Bavarian Nordic sells US Priority Review Voucher for USD160m
Clarity Pharmaceuticals agrees commercial manufacturing deal for Cu-64 SAR-bisPSMA with SpectronRx
Solve M.E. names Simmaron Research as ME/CFS Catalyst Award recipient
RemeGen's telitacicept (RC18) granted European Orphan Drug Designation for myasthenia gravis
CSL's ANDEMBRY (garadacimab-gxii) approved by US FDA for hereditary angioedema treatment
Celltrion's STEQEYMA (ustekinumab-stba) receives additional US FDA approval
ArkBio's NDA for Azstarys accepted and granted Chinese regulatory Priority Review
InspireMD secures CE Mark approval for CGuard Prime EPS under European MDR
FDA approves Merck's KEYTRUDA for perioperative use in PD-L1+ head and neck cancer
Alligator Bioscience gains FDA support for Phase 3 mitazalimab dose in pancreatic cancer